These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26437753)

  • 1. [Boosted protease inhibitor monotherapy in HIV-infected patients: results of a study in a real life setting].
    Di Benedetto N; Montero-Alonso M; Blanes M; Lacruz J; Cuellar S; Calabuig E; López J; Salavert M
    Rev Esp Quimioter; 2015 Oct; 28(5):235-41. PubMed ID: 26437753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
    Yunquera-Romero L; Asensi-Díez R; Del Rio-Valencia JC; Muñoz-Castillo I; Castaño-Carracedo MA
    Rev Esp Quimioter; 2016 Dec; 29(6):308-317. PubMed ID: 27888600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
    Santos JR; Llibre JM; Bravo I; García-Rosado D; Cañadas MP; Pérez-Álvarez N; Paredes R; Clotet B; Moltó J
    AIDS Res Hum Retroviruses; 2016 May; 32(5):452-5. PubMed ID: 26781004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
    AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
    AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group.
    Curran A; Monteiro P; Domingo P; Villar J; Imaz A; Martínez E; Fernández I; Knobel H; Podzamczer D; Iribarren JA; Peñaranda M; Crespo M;
    J Antimicrob Chemother; 2014 May; 69(5):1390-6. PubMed ID: 24415645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
    Gianotti N; Cozzi-Lepri A; Antinori A; Castagna A; De Luca A; Celesia BM; Galli M; Mussini C; Pinnetti C; Spagnuolo V; d'Arminio Monforte A; Ceccherini-Silberstein F; Andreoni M;
    PLoS One; 2017; 12(2):e0171611. PubMed ID: 28192453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
    HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
    Möller J; Desai K; Simpson K; Baran RW; Van de Steen O; Dietz B; Gooch K
    J Med Econ; 2014 Apr; 17(4):250-8. PubMed ID: 24351091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
    Rojas Sánchez P; Prieto L; Jiménez De Ory S; Fernández Cooke E; Navarro ML; Ramos JT; Holguín Á;
    PLoS One; 2017; 12(3):e0173168. PubMed ID: 28350802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject.
    Negredo E; Bonjoch A; Puig J; Echeverría P; Estany C; Santos JR; Moltó J; Pérez-Álvarez N; Ornelas A; Clotet B
    New Microbiol; 2015 Apr; 38(2):193-9. PubMed ID: 25938744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
    Brogan A; Mauskopf J; Talbird SE; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
    Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.
    Arribas JR; Girard PM; Paton N; Winston A; Marcelin AG; Elbirt D; Hill A; Hadacek MB
    HIV Med; 2016 May; 17(5):358-67. PubMed ID: 26709605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Darunavir as first-line therapy. The TITAN study].
    Curran A; Ribera Pascuet E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():14-22. PubMed ID: 19195455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
    HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.
    Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Casado JL;
    Infect Dis (Lond); 2020 Mar; 52(3):202-206. PubMed ID: 31760833
    [No Abstract]   [Full Text] [Related]  

  • 20. Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice.
    Santos JR; Curran A; Navarro-Mercade J; Ampuero MF; Pelaez P; Pérez-Alvarez N; Clotet B; Paredes R; Moltó J
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):513-518. PubMed ID: 30909716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.